Does rosiglitazone increase the risk of heart failure events in people with type 2 diabetes?
Rosiglitazone increases the risk of heart failure events in patients with type 2 diabetes and should be discontinued if symptomatic HF develops.
These findings confirm the increased risk of HF events in people treated with rosiglitazone and support the recommendation that this agent should not continue to be used in people developing symptomatic HF while using the medication. Close follow-up for the risk of HF should be offered to elderly people, people with markedly increased body mass index, people with microalbuminuria/proteinuria, and people with increased systolic blood pressure.
Komajda et al. (Fri,) studied this question.